Most patients with primary CNS lymphoma (PCNSL)relapse
tion of the antibody was demonstrated in four of the six patients examined by SPECT imaging with 111 In ibritumomab tiuxetan. All patients experienced grade 3/4 hematotoxicity but no acute neurotoxicity. Penetration of a therapeutic antibody into PCNSL and significant clinical activity was shown. Because of limited response duration and considerable hematotoxicity, future investigations should focus on a multimodal approach with additional chemotherapy and preferably autologous stem cell support. Neuro- Oncology 11, [423] [424] [425] [426] [427] [428] [429] Y ibritumomab tiuxetan, CNS lymphoma, imaging, PCNSL, Zevalin P rimary CNS lymphoma (PCNSL) is a rare type of usually aggressive B-cell non-Hodgkin's lymphoma exclusively involving the CNS. Standard salvage therapy has not yet been established. Despite remission of PCNSL after primary therapy in the majority of patients, relapse occurs within 1-2 years in 30%-60% of patients, with a median survival after relapse of only 2-4 months. 1 The anti-CD20 monoclonal antibody rituximab expanded treatment options in systemic B-cell lymphoma. 2 T he radiolabeled anti-C D20 antibody yttrium-90 ( 90 Y) ibritumomab tiuxetan (Zevalin, Bayer Schering Pharma, Berlin, Germany) has demonstrated efficacy in systemic lymphomas even refractory to chemotherapy and rituximab, with only one treatment course needed. 3 Due to the large molecular size of 145 kDa, rituximab poorly penetrates the blood-brain barrier (BBB), 4 which limits its use in PCNSL. According to PET, the BBB is initially leaky in PCNSL and reconstitutes after therapy-induced tumor shrinkage within 5 weeks. 5 Therefore, a sufficient amount of 90 Y ibritumomab tiuxetan (148 kDa) might be delivered to the tumor bulk in one treatment course.
The aim of this study was to evaluate the therapeutic efficacy, tumor penetration, and toxicity of 90 Y ibritumomab tiuxetan in recurrent PCNSL.
Patients and Methods

Study Design
We planned to treat 10 patients with relapsed or refractory PCNSL in this phase II study. Primary end points were overall response and ibritumomab tiuxetan biodistribution; secondary end points were response duration, survival, and toxicity, including late neurotoxicity.
Inclusion criteria were histologically confirmed relapsed PCNSL after at least one prior treatment, age > 18 years, KPS > 60, and human immunodeficiency virus (HIV) negativity. Exclusion criteria were evidence of systemic lymphoma, active infection, severe concomitant disease, inadequate cardiac, liver, and kidney function, and abnormal hematological parameters.
The study was approved by the local ethics committee, and informed consent was obtained from all patients.
Y ibritumomab tiuxetan therapy
An infusion of rituximab at 250 mg/m 2 was given 8 days and 4 h before 90 Y ibritumomab tiuxetan therapy to improve biodistribution of the radiolabeled antibody by binding to peripheral CD20
1 B-cells. 90 Y ibritumomab tiuxetan was given intravenously according to the standard regimen.
Seven patients were simultaneously treated with dexamethasone (2-8 mg three times daily) for 1 month. No concomitant antineoplastic therapy was given to the patients.
Biodistribution and Tumor Uptake
To evaluate antibody uptake in PCNSL after systemic intravenous administration, a dosimetric measurement study with ibritumomab tiuxetan labeled with the gamma emitter indium-111 ( 111 In) was performed in patients 1-6. These patients received 170-190 MBq of the gamma emitter after the first rituximab administration on day -8. On a SPECT/CT system (Hawkeye Millenium, GE Medical Systems, Slough, UK), whole-body scans and single-photon-emission CT (SPECT) were performed 1 h and 2-5 days thereafter. Regions of interest (ROIs) were drawn around the tumor regions that were localized by SPECT/CT performed on day -8 and/or pretreatment brain MRI. The mean uptake values (counts/ minute/pixel) were divided by the values determined in ROIs of the adjacent regions (background). The ratios were corrected for physical decay of 111 In (see Fig. 2 ).
Response Evaluation
Response evaluation by contrast-enhanced MRI was scheduled before and 1 and 3 months after treatment as well as every 3 months thereafter in responders or if clinically indicated, according to the International PCNSL Collaborative Group criteria. 6 Additional imaging by 18 F-fluorodeoxyglucose-PET (FDG-PET) was performed in patient 9 before treatment and in patient 6 before and 1 month after treatment parallel to MRI.
Results
Patient Characteristics
Ten patients with median age of 53.5 years (range, 41-79 years) and median KPS scores of 80% were included. Histology, obtained at first diagnosis, revealed diffuse largecell B-cell lymphoma in all patients except patient 10, who had low-grade B-cell lymphoma. Patients received a median of three previous therapies (range, 1 to 7), including five patients that received previous whole-brain irradiation. Patient characteristics are given in Table 1 .
Nine patients received the intended antibody treatment; patient 4, with concomitant diabetes and steroid treatment, was withdrawn due to pulmonary aspergillosis diagnosed after the first rituximab application and SPECT imaging but before treatment with 90 Y ibritumomab tiuxetan.
SPECT Imaging with 111
In Ibritumomab Tiuxetan
Imaging with 111 In ibritumomab tiuxetan was performed in patients 1-6. Pretreatment MR images of these patients are shown in Fig. 1 . SPECT revealed no lymphoma uptake in patients 1 and 6. Patients 3-5 showed prominent uptake in the tumors (Fig. 2) . In patient 2, tumor uptake was assessable only by ROI evaluation (Fig. 3) .
Overall Response and Response Duration
Four of the nine evaluable patients responded to 90 Y ibritumomab tiuxetan treatment: Two patients showed complete response (CR) along with brief neurological improvement (patient 6 [see Fig. 4 ] and patient 7); one of them concomitantly received steroids. FDG-PET, performed before treatment and 4 weeks thereafter, in patient 6 showed decreased but still detectable FDG uptake. MRI, performed due to neurological deterioration, detected relapse with new lesions distant to the original target within 4 weeks in both patients. Uncertain complete remission on MRI with minimal residual contrast enhancement and neurological improvement after termination of steroid treatment was found in patient 10 and has been confirmed more than 30 months post- None of the patients with prominent tumor uptake in SPECT responded to treatment. Patient 2, with PR, had uptake assessable only by ROI evaluation, and patient 6, with CR, showed no uptake in SPECT. Results for individual patients are given in Table 2 . and pulmonary aspergillosis prior to treatment with 90 Y ibritumomab tiuxetan in patient 4 (see Table 2 ).
Discussion
Imaging with 111 In ibritumomab tiuxetan provided evidence that the antibody is able to cross the BBB at this stage of disease and accumulates within the target area 48 h and more after application. Furthermore, four of nine patients showed clinical responses to treatment with 90 Y ibritumomab tiuxetan. In a series of four patients with PCNSL, Dietlein et al. 7 were not able to detect accumulation of iodine-123 ( 123 I)-labeled rituximab within the tumor on SPECT 1, 24, or 48 h after application. These time points were chosen based on quick in vivo dehalogenation of the compound and short physical half-life of 123 I (13 h). In our study, however, we used a murine anti-CD20 antibody firmly conjugated to tiuxetan and 111 In, which has a longer physical half-life (67 h). We postulate a delayed accumulation of the antibody in PCNSL in some patients due to remaining barrier function of the leaky BBB, demonstrated in patients 2 and 6 without assessable uptake (scan reading and uptake ratios) up to 6 days following administration but both showing at least PR. The clinical response in patients without uptake (especially in this small number of patients) is not surprising, because in larger imaging studies with other lymphomas a good correlation between nuclear medicine and clinical response could not always be shown. Iwamoto et al. 8 investigated 111 In ibritumomab tiuxetan uptake in six PCNSL patients and found a 10-fold higher median dose of radiation in the lymphoma compared with normal brain tissue. Scans were acquired for up to 7 days following injection of 111 In ibritumomab tiuxetan. The median clearance half-life within the lymphoma in this small patient cohort was calculated to be 96 h (range, 17-180 h), but no data were given regarding the time of maximum uptake.
We have not performed dosimetry in our patients. Doses reported by Iwamoto et al. 8 ranged from 2 to 1,818 cGy (median, 701 cGy) within the lymphoma and only 17-130 cGy (median, 70 cGy) in normal brain tissue. With respect to neurotoxicity, we would not expect these doses to cause significant neurotoxicity even in patients pretreated with whole-brain irradiation. Sakamoto et al. 9 reported on the use of stereotactic irradiation with concomitant chemotherapy in a small cohort of patients with PCNSL after prior whole-brain irradiation. They observed clinical activity in the absence of acute neurotoxicity. This is indicative of the radiosensitivity of PCNSL even in the recurrent situation. The penetration of large molecules such as antibodies into the brain is limited to bulky tumor areas with at least partially disrupted BBB. Therefore, areas with small tumor cell accumulations with an intact BBB not visualized by MRI, as must be suspected in PCNSL, might not be reached by the antibody. This could explain why the observed responses were extremely short-lived, with new lesions occurring distant of the target tumor.
One approach to reach lymphoma cells beyond the BBB is to deliver treatment after prior osmotic BBB disruption by intra-arterial mannitol infusion. However, this approach requires adequate experience and careful patient selection. Doolittle et al. 10 report on four patients receiving rituximab and chemotherapy after prior BBB disruption. To our knowledge, no treatment with 90 Y ibritumomab tiuxetan after BBB disruption has been reported thus far.
The toxicity observed was similar to that seen in other studies of 90 Y ibritumomab tiuxetan, with thrombocytopenia and leukopenia occurring approximately 4 weeks after therapy. Patients need to be closely monitored for hematological toxicity and infection. Importantly, no acute neurotoxicity was observed.
To date, experience with 90 Y ibritumomab tiuxetan in PCNSL is limited to a few case reports including combination treatment with temozolomide [10] [11] [12] [13] and a small study of six patients with recurrent PCNSL including imaging with 111 In ibritumomab tiuxetan.
The present study is the largest so far to investigate 90 Y ibritumomab tiuxetan treatment in PCNSL, demonstrating penetration into PCNSL along with significant clinical activity. In contrast to the study reported by Iwamoto et al., 8 we saw complete disappearance of the tumor lesion in three of our patients. However, responses in our heavily pretreated patient cohort were short, and relapses occurred distant to target lesions. Moreover, we observed considerable delayed hematotoxicity causing infectious complications and interfering with salvage treatment. Despite the evidence of tumor penetration, monotherapy with 90 Y ibritumomab tiuxetan proved not to be sufficient for the treatment of recurrent PCNSL in our heavily pretreated patient cohort. Based on experiences with rituximab in high-grade lymphomas, combination of radioimmunotherapy with chemotherapy seems desirable. However, due to the observed hematotoxicity, such a multimodal approach would require autologous stem cell support. 
